Flosequinan in heart failure: acute haemodynamic and longer term symptomatic effects.

Effect of flosequinan on exercise capacity and symptoms in severe heart failure.

“…The upper boundary on the sequential analysis plan had been reached after six patient pairs had completed week 8 (p < 0-05) (fig 1), but the final pair were allowed to complete the trial. To reach this point, ten patient pairs had been entered.…”

The effects of flosequinan on submaximal exercise in patients with chronic cardiac failure.

“…It is likely that the reduction in yE during submaximal exercise observed in this and earlier studies (Cowley et al, 1988) (Cowley et al, 1988;Kessler & Parker, 1987). Time (weeks) Figure 1 Cardiopulmonary parameters during submaximal exercise in a group of patients with chronic cardiac failure before and after 2 and 8 weeks treatment with placebo or flosequinan 100 mg daily.…”

Acute and chronic effects of flosequinan on resting and exercise haemodynamics in congestive heart failure

“…In patients with congestive heart failure following acute myocardial infarction, the peak haemodynamic effect was observed at 1-2 h post dose [16] with persistent effects over the 4 h post-dose study period. Further acute haemodynamic studies in patients with heart failure have shown significant resting haemodynamic effects up to 24 h post dose [14,15]. In non-invasive studies of patients with chronic congestive heart failure, flosequinan has been shown to improve exercise tolerance after 4 [15] and 8 weeks treatment [17].…”

“…It has a hypotensive action [11,12] and, in patients with congestive heart failure, it has been shown to decrease resting preload and afterload while improving cardiac performance [13][14][15]. In patients with congestive heart failure following acute myocardial infarction, the peak haemodynamic effect was observed at 1-2 h post dose [16] with persistent effects over the 4 h post-dose study period.…”

“…Further acute haemodynamic studies in patients with heart failure have shown significant resting haemodynamic effects up to 24 h post dose [14,15]. In non-invasive studies of patients with chronic congestive heart failure, flosequinan has been shown to improve exercise tolerance after 4 [15] and 8 weeks treatment [17]. No Three constrast variables, phase, treatment and time (pre-exercise, 3 min and 6 min during exercise) were used to analyse data from the bicycle exercise tests, again using a repeated measures model.…”